The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.
May 17th 2024
The FDA has approved tarlatamab (Imdelltra; Amgen), a novel bispecific T-cell engager, to treat patients with extensive-stage small cell lung cancer (SCLC).
December 14th 2023
Researchers Identify Potential Biomarkers for Combination Treatment Efficacy in NSCLC
March 3rd 2022A recent study demonstrates certain driver mutations in patients with non–small cell lung cancer (NSCLC) may shorten disease-free survival after combination neoadjuvant immunotherapy and chemotherapy.
Read More
PRO-Based Symptom Management Improves Postdischarge Outcomes After Lung Cancer Surgery
February 15th 2022Patients who utilized a patient-reported outcome (PRO) symptom measurement tool reported superior postdischarge outcomes after lung cancer surgery compared with those who received usual care.
Read More
Meta-Analysis Points to Beneficial Role of Dexamethasone Pretreatment in NSCLC
February 2nd 2022A meta-analysis on first-line treatment for non–small cell lung cancer (NSCLC) in clinical trials revealed that inclusion of dexamethasone along side chemotherapy and PD-L1 inhibitors yielded benefits in this patient population.
Read More
Model Could Help Screen NSCLC Patients Likely to Benefit From Anti–PD-L1 Immunotherapy
January 19th 2022A model developed by researchers in China could help identify patients with non–small cell lung cancer (NSCLC) most likely to benefit from anti– programmed death-ligand 1 (PD-L1) immunotherapy.
Read More
Study: USPSTF 2021 Lung Cancer Update Helped Mitigate Screening Racial Disparities
January 13th 2022A new analysis published in JAMA Oncology found the United States Preventive Services Task Force's (USPSTF) 2021 update to lung cancer screening recommendations helped close a racial disparity gap in screening rates.
Read More
Cost-effectiveness of Nivolumab in Patients With NSCLC in the United States
This article presents a cost-effectiveness analysis of nivolumab vs docetaxel from the US payer perspective in non–small cell lung cancer (NSCLC) based on randomized phase 3 studies with a minimum 5 years of follow-up.
Read More
An Inside Look at Disparities in Lung Cancer Care for At-Risk Populations
August 1st 2021On World Lung Cancer Day, we explore current guidelines for lung cancer screening in the United States, implications of the COVID-19 pandemic, and disparities in mortality and access to care by race and socioeconomic status.
Read More
Insights on Small-Cell Lung Cancer NCCN Guidelines
April 4th 2021Kathryn Gold, MD, medical oncologist and associate professor of medicine at UC San Diego, who is a member of the NCCN guidelines panel for small-cell lung cancer, gives insight into the guidelines and the importance of frequent updates.
Read More
FDA Approves Osimertinib for Adjuvant Treatment of Early-Stage EGFR-Mutated NSCLC
February 16th 2021The new indication for osimertinib (Tagrisso) marks the first FDA approval of an adjuvant treatment for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations.
Read More
Certain NSCLC Patients Are More Likely to Respond to Immunotherapy, Study Results Show
February 16th 2021A recent study investigated what makes some non-small cell lung cancer patients with a type of human leukocyte antigen (HLA) called B44 are more likely than others to respond to immunotherapy.
Read More
Possible Treatment Identified for Aggressive NSCLC Subset
February 16th 2021Researchers from the Children’s Medical Center Research Institute at the University of Texas Southwestern discovered a potential treatment for patients with non–small cell lung cancer (NSCLC) who have KRAS and LKB1 mutations.
Read More